News

Activation Capital Launches Start-the-Journey: Pre-Accelerator Program

Activation Capital proudly announces the launch of Start-the-Journey, a new BioHealth Pre-Accelerator designed to equip early-stage biotech and life science entrepreneurs with the knowledge and tools to build successful startups. Powered by Fat Robin Consulting, this innovative program supports founders in the initial phases of their entrepreneurial journey, preparing them for more advanced initiatives like Activation Capital’s Frontier BioHealth, launched earlier this year to support scaling advanced-stage startups.

The launch of Start-the-Journey comes as Central Virginia’s biotech and life sciences sector continues to thrive. The region has experienced significant advancements, including the growth of its pharmaceutical manufacturing cluster and an expansion of biotech educational programs at local universities. With local research institutions expanding their biotech offerings, Central Virginia is becoming a recognized hub for life sciences innovation. Activation Capital is committed to supporting this ecosystem by helping early-stage entrepreneurs build a solid foundation through Start-the-Journey and its later-stage program Frontier BioHealth.

“This program provides a foundational experience for entrepreneurs navigating the early challenges of building a biohealth startup. Our goal is to help them develop the essential skills needed to succeed,” said Dr. Jim Pannucci, Vice President of Entrepreneurship at Activation Capital.

The program, with content provided by Fat Robin Consulting, includes a personalized intake session for each startup, offering tailored guidance from experts. Cohorts will operate on a rolling model, starting monthly from October 2024 through January 2025. Participants will cover critical topics such as entrepreneurial qualities, market value creation, MVP development, and key resources for entrepreneurs.

Seema Sood, CEO and Founder of Fat Robin Consulting, expressed enthusiasm for the program: “We’re excited to work with founders who are shaping the future of biotech. A strong foundation on entrepreneurship will scaffold the long-term success of young companies.”

Start-the-Journey is ideal for founders in Richmond, across Virginia, or those considering locating their company in the state, with a focus on deep-tech biotechnology, pharmaceuticals, medical devices, and diagnostics. Offered at no cost, the program is designed to reduce financial burdens for early-stage entrepreneurs, and Activation Capital takes no founder equity.

“We’re excited about the potential impact Start-the-Journey will have in fostering innovation and accelerating the growth of Virginia’s BioHealth sector,” Pannucci added. Additional information can be found at https://activation.capital/start-the-journey/.

Start-the-Journey is funded in part through a grant with the U.S. Small Business Administration (SBA). All opinions, conclusions, and/or recommendations expressed herein are those of Activation Capital and do not necessarily reflect the views of the SBA.

Learn more here.

Recent News

10/22/2024

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces the further expansion of its on-going Netherton Syndrome (NS) clinical studies to include two additional international sites in the United Kingdom (UK). These sites, Great Ormond Street Hospital and St. Thomas’ Hospital,

10/21/2024

AgroSpheres and BASF Announce Major Strategic Partnership

AgroSpheres, a biotechnology leader in sustainable crop protection and crop health, and BASF, a global leader in agricultural solutions, are excited to announce their strategic partnership on a category defining novel bioinsecticide. This collaboration marks a significant step forward in sustainable agriculture solutions aimed at enhancing crop protection. The companies are working together to develop

10/17/2024

Charlottesville startup KeViRx tackles acute lung injuries

Charlottesville startup KeViRx Inc. is developing new drugs that target inflammation for people with acute lung injuries. The company received a $2 million grant from the Department of Defense for further research to grow from animal testing to preparing for an investigational new drug meeting with the Food and Drug Administration. KeViRx’s goal is to